Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.

Vatsyayan R, Singhal J, Nagaprashantha LD, Awasthi S, Singhal SS.

Mol Carcinog. 2013 Jan;52(1):39-48. doi: 10.1002/mc.20875. Epub 2011 Oct 17.

2.
3.

Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

Radulovic S, Bjelogrlic SK.

J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.

PMID:
17935273
4.
5.

Recent advances in the therapeutic perspectives of Nutlin-3.

Secchiero P, Bosco R, Celeghini C, Zauli G.

Curr Pharm Des. 2011;17(6):569-77. Review.

PMID:
21391907
6.

State of the art of the therapeutic perspective of sorafenib against hematological malignancies.

Zauli G, Voltan R, Tisato V, Secchiero P.

Curr Med Chem. 2012;19(28):4875-84. Review.

PMID:
22934770
7.

p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Noon AP, Vlatković N, Polański R, Maguire M, Shawki H, Parsons K, Boyd MT.

Cancer. 2010 Feb 15;116(4):780-90. doi: 10.1002/cncr.24841. Review.

8.

Dissecting p53-dependent apoptosis.

Chipuk JE, Green DR.

Cell Death Differ. 2006 Jun;13(6):994-1002. Review.

9.

Cell death pathology: the war against cancer.

Rufini A, Melino G.

Biochem Biophys Res Commun. 2011 Oct 28;414(3):445-50. doi: 10.1016/j.bbrc.2011.09.110. Epub 2011 Sep 28. Review.

PMID:
21971555
10.

p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.

Rao B, Lain S, Thompson AM.

Br J Cancer. 2013 Dec 10;109(12):2954-8. doi: 10.1038/bjc.2013.702. Epub 2013 Nov 14. Review.

11.

Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma.

Ye DW, Zhang HL.

Onco Targets Ther. 2014 Jun 6;7:925-35. doi: 10.2147/OTT.S41828. eCollection 2014. Review.

12.

Targeting the Met signaling pathway in renal cancer.

Giubellino A, Linehan WM, Bottaro DP.

Expert Rev Anticancer Ther. 2009 Jun;9(6):785-93. doi: 10.1586/era.09.43. Review.

13.

Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.

Zustovich F, Lombardi G, Pastorelli D, Farina P, Bianco MD, De Zorzi L, Palma MD, Nicoletto O, Zagonel V.

Open Access J Urol. 2011 May 10;3:69-82. doi: 10.2147/OAJU.S7230. Review.

Supplemental Content

Support Center